\u27Vitamin D and cognition in older adults\u27: updated international recommendations. by Annweiler, C et al.
Western University
Scholarship@Western
Medical Biophysics Publications Medical Biophysics Department
1-2015
'Vitamin D and cognition in older adults': updated
international recommendations.
C Annweiler
Western University, cannweil@uwo.ca
E Dursun
F Féron
D Gezen-Ak
A V Kalueff
See next page for additional authors
Follow this and additional works at: https://ir.lib.uwo.ca/biophysicspub
Part of the Medical Biophysics Commons
Citation of this paper:
Annweiler, C; Dursun, E; Féron, F; Gezen-Ak, D; Kalueff, A V; Littlejohns, T; Llewellyn, D J; Millet, P; Scott, T; Tucker, K L;
Yilmazer, S; and Beauchet, O, "'Vitamin D and cognition in older adults': updated international recommendations." (2015). Medical
Biophysics Publications. 32.
https://ir.lib.uwo.ca/biophysicspub/32
Authors
C Annweiler, E Dursun, F Féron, D Gezen-Ak, A V Kalueff, T Littlejohns, D J Llewellyn, P Millet, T Scott, K
L Tucker, S Yilmazer, and O Beauchet
This article is available at Scholarship@Western: https://ir.lib.uwo.ca/biophysicspub/32
Click here to view the article Editorial Comment by M. F. Holick doi: 10.1111/joim.12279
‘Vitamin D and cognition in older adults’: updated
international recommendations
C. Annweiler1,2, E. Dursun3, F. Feron4, D. Gezen-Ak3, A. V. Kalueff5, T. Littlejohns6, D. J. Llewellyn6, P. Millet4,
T. Scott7, K. L. Tucker8, S. Yilmazer3 & O. Beauchet1
From the 1Department of Neuroscience, Division of Geriatric Medicine and Memory Clinic, UPRES EA 4638, UNAM, Angers University
Hospital, Angers, France; 2Department of Medical Biophysics, Robarts Research Institute, Schulich School of Medicine and Dentistry, the
University of Western Ontario, London, ON, Canada; 3Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University,
Istanbul, Turkey; 4CNRS, NICN UMR 7259, Aix Marseille Universite, Marseille, France; 5ZENEREI Institute, Slidell, LA, USA; 6University of
Exeter Medical School, Exeter, UK; 7Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA; and
8Department of Clinical Laboratory and Nutritional Sciences, University of Massachusetts, Lowell, MA, USA
Abstract. Annweiler C, Dursun E, Feron F, Gezen-Ak
D, Kalueff AV, Littlejohns T, Llewellyn DJ, Millet P,
Scott T, Tucker KL, Yilmazer S, Beauchet O (Angers
University Hospital, Angers, France; University of
Western Ontario, London, ON, Canada; Istanbul
University, Istanbul, Turkey; Aix Marseille
Universite, Marseille, France; ZENEREI Institute,
Slidell, LA, USA; University of Exeter Medical
School, Exeter, UK; Tufts University, Boston, MA,
USA; University of Massachusetts, Lowell, MA,
USA). ‘Vitamin D and cognition in older adults’:
updated international recommendations (Review).
J Intern Med 2015; 277: 45–57.
Background. Hypovitaminosis D, a condition that is
highly prevalent in older adults aged 65 years and
above, is associated with brain changes and
dementia. Given the rapidly accumulating and
complex contribution of the literature in the field
of vitamin D and cognition, clear guidance is
needed for researchers and clinicians.
Methods. International experts met at an invitational
summit on ‘Vitamin D and Cognition in Older
Adults’. Based on previous reports and expert
opinion, the task force focused on key questions
relating to the role of vitamin D in Alzheimer’s
disease and related disorders. Each question was
discussed and voted using a Delphi-like approach.
Results. The experts reached an agreement that
hypovitaminosis D increases the risk of cognitive
decline and dementia in older adults and may alter
the clinical presentation as a consequence of
related comorbidities; however, at present, vitamin
D level should not be used as a diagnostic or
prognostic biomarker of Alzheimer’s disease due to
lack of specificity and insufficient evidence. This
population should be screened for hypovitaminosis
D because of its high prevalence and should receive
supplementation, if necessary; but this advice was
not specific to cognition. During the debate, the
possibility of ‘critical periods’ during which vitamin
D may have its greatest impact on the brain was
addressed; whether hypovitaminosis D influences
cognition actively through deleterious effects and/
or passively by loss of neuroprotection was also
considered.
Conclusions. The international task force agreed on
five overarching principles related to vitamin D and
cognition in older adults. Several areas of uncer-
tainty remain, and it will be necessary to revise the
proposed recommendations as new findings
become available.
Keywords: Alzheimer’s disease, brain, cognition, neu-
roendocrinology, older adults, vitamin D.
Introduction
About 1 billion individuals worldwide are estimated
to have hypovitaminosis D (i.e. inadequate levels of
serum 25-hydroxyvitamin D (25OHD) below
75 nmol L1 or 30 ng mL1) [1, 2]. In addition to
regulating bone metabolism, vitamin D exerts
multiple biological actions mediated by the nuclear
hormone vitamin D receptor (VDR) [2–7]. New
target organs, such as the central nervous system
(CNS), and evidence for a neurosteroid action of
vitamin D have been reported [3–8]. The need to
explore the adverse impact of vitamin D depriva-
tion on the ageing brain seems especially
important because nearly one in two older adults
(i.e. aged 65 years and above) [2] and 70–90% of
ª 2014 The Association for the Publication of the Journal of Internal Medicine 45
Review
adults with cognitive difficulties [9] have hypovita-
minosis D. Together, this raises the possibility that
vitamin D plays a role in the natural history of
cognitive dysfunction, including Alzheimer’s dis-
ease (AD) and related disorders (ADRDs) [9–13].
Because of the rapidly accumulating and complex
contribution of both basic and clinical research in
this field, an invitational summit of leading experts
was convened in order to (i) identify areas clearly
supported by the literature, (ii) nuance findings
that remain not proven, (iii) raise new research
questions and (iv) provide clear guidelines to the
medical and scientific communities.
Methods
Consensus finding at the invitational summit of
experts consisted of a three-step process. In the
first step, in February 2013, the first author (CA)
invited leading international experts, including
physicians and scientists from a wide range of
disciplines identified on the basis of their relevant
publications and citations, to form an international
task force. All invited experts accepted the need for
a task force and agreed to meet at an invitational
summit.
In the second step, all experts communicated by
email with the first author to better identify
respective areas of expertise, discuss unmet needs
and potential learning objectives in the field and
propose a holistic approach to the issue of ‘vitamin
D and cognition’ based on the expertise of all
participants. After discussion, the following pro-
gramme was approved by all: (i) neurosteroid
properties of vitamin D (KLT and TS); (ii) contribu-
tion of transgenic animal models to understanding
the neurological effects of vitamin D (AVK); (iii)
vitamin D and ADRDs: lessons from animal models
(FF); (iv) brain changes associated with hypovita-
minosis D (CA); (v) polymorphisms of vitamin D
receptors: clinical implication for human variants
(ED and DGA); (vi) cognitive disorders and hypovi-
taminosis D: observational approach (DJL and TL);
and (vii) vitamin D intake and cognition: interven-
tional approach (OB).
In the third step, the task force met in person on 15
July 2013 at the invitational summit in Boston,
MA, USA. After presentations relating to each
aspect of the programme, group discussions were
held to attempt to identify consensus and disagree-
ments, in order to highlight knowledge gaps and to
emphasize key messages for the scientific and
medical communities. Finally, the discussion
focused on five key questions regarding the impli-
cations of vitamin D as a risk factor for ADRDs, as
a diagnostic and/or prognostic biomarker of
ADRDs, as an explanation of the variability of the
clinical manifestations of ADRDs and the potential
benefits of vitamin supplementation D in the
management of ADRDs (Table 1). The 10 experts
voted on each key questions: ‘yes’ (agreement) or
‘no’ (disagreement). It was agreed that questions
supported by ≥75% of ‘yes’ votes would be imme-
diately accepted whereas those with <25% would
be rejected outright. Others would be subjected to
Table 1 Position of experts on key questions related to ‘Vitamin D and cognition in older adults’
Questions
Experts’ answers
(n = 10) Agreement
percentage (%)Yes No
Can hypovitaminosis D be considered an aetiological/risk
factor for cognitive disorders/ADRDs?
10 0 100
Can serum vitamin D status be considered a useful biomarker
for the diagnosis of ADRDs?
1 9 90
Can serum vitamin D status be considered useful for determining
the prognosis of ADRDs?
0 10 100
Can serum vitamin D status explain part of the variability in
symptoms of ADRDs in older adults?
10 0 100
Should vitamin D supplementation be part of the care management
of older adults with cognitive disorders/ADRDs?
9 1 90
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further discussion and subsequent voting, where
≥67% support or, in an eventual third round, a
majority of ≥50% would be needed for acceptance.
After the face-to-face meeting, the statements were
distributed to the committee members by email for
final comments. Only suggestions for improve-
ments for clarity of wording or to address redun-
dancies were considered, whilst changes to the
meaning were not accepted.
Results
Overview of the research topic
At the beginning of the summit, the experts
discussed the current status of the research topic.
Neurosteroid properties of vitamin D: involvement in
neurophysiology
Vitamin D enters the cerebrospinal fluid (CSF) and
brain by crossing the blood–brain barrier (BBB) via
passive diffusion and via specific carriers in the
cerebral capillaries or the blood–CSF barrier in the
plexus choroideus [14, 15]. The concentration of
25OHD (circulating form of vitamin D) in the CSF
positively correlates with that in the serum under
physiological conditions [14]. In situ, vitamin D
exerts most of its actions through its nuclear
hormone receptor the VDR, which is expressed in
neuronal and glial cells in almost all regions of the
CNS. In particular, the VDR is expressed in the
hippocampus, hypothalamus, cortex and subcor-
tex [5–7], the areas essential for cognition. The
active form of vitamin D, 1,25-dihydroxyvitamin D
(1,25OHD), has a trophic function of neuronal
differentiation and maturation via control of the
synthesis of neurotrophic agents such as nerve
growth factor (NGF) and glial cell line-derived
neurotrophic factor (GDNF) [7, 16]. It also acceler-
ates neuronal growth in rat hippocampal cell
cultures [16]. Moreover, 1,25OHD regulates the
genetic expression of numerous neurotransmitters
in the brain, including acetylcholine, dopamine,
serotonin and c-aminobutyric acid, notably in the
hippocampus [4, 5].
Neurosteroid properties of vitamin D: neuroprotec-
tive action
Vitamin D appears to enhance neuronal defence.
Studies in mice have demonstrated that vitamin D
may reverse age-related inflammatory changes in
the hippocampus [17]. Vitamin D has also been
shown to attenuate amyloid-b (Ab) 42 accumula-
tion by stimulating phagocytosis of the Ab peptide
[18], and enhance brain-to-blood Ab efflux
transport at the BBB [19], resulting in a decreased
number of amyloid plaques [20]. In addition, it
was reported that vitamin D regulates intraneu-
ronal calcium homoeostasis via the regulation of
voltage-gated calcium channels [21], including
those targeted by Ab [22], supporting the idea
that vitamin D has the potential to rearrange
neuronal calcium homoeostasis altered by the Ab
peptide. Finally, vitamin D was shown to exhibit
neuroprotective properties against glutamate tox-
icity [23, 24] through the upregulation of VDR
expression [23] and antioxidant effects [24].
Indeed, it has been reported that vitamin D
protects against free radicals generated by reactive
species of oxygen [24] and nitric oxide [25],
inhibits the synthesis of inducible nitric oxide
synthase [26] and regulates the activity of the c-
glutamyl transpeptidase [4], which is a key
enzyme involved in the antioxidant metabolism of
glutathione.
Interestingly, these effects relate to mechanisms
implicated in the pathogenesis of AD (Fig. 1),
which suggests that the lack of vitamin D may
explain at least part of the natural history of this
disease [27].
Hypovitaminosis D and/or inefficient utilization of
vitamin D: which is most important?
Accumulating evidence suggests that hypovita-
minosis D could be associated with the pathogen-
esis of AD. However, based on recent findings
from in vitro studies that the vitamin D pathway is
the target of Ab-induced toxicity in AD, this
question can be addressed in a different way.
Essentially, Ab renders neurons deficient in vita-
min D by increasing the degradation of active
vitamin D and VDR [22, 28]. This may be referred
to as ‘inefficient utilization of vitamin D’. Ab may
disrupt the utilization of vitamin D in the brain
even if the systemic concentration meets the
requirements of the brain. Any alteration in genes
related to the action of vitamin D, including its
receptors (VDR and 1,25-MARRS [membrane
associated, rapid response steroid-binding]),
enzymes related to its metabolism or transporters,
may also result in inefficient utilization of vitamin
D, thus making neurons vulnerable to neurode-
generation [22, 28–32]. This possibility is sup-
ported by the association between AD and
polymorphisms of VDR and megalin [30, 31, 33]
and the toxic effects of VDR and 1,25-MARRS
suppression in neurons [29, 32, 34]. Although
hypovitaminosis D and inefficient utilization of
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vitamin D seem to be two different variables,
crosstalk between the two should not be ignored
when considering the pathogenesis of AD.
Consequences of the inefficient utilization of vitamin
D on phenotype: the VDR knockout mouse model
The VDR knockout (VDR-/-) mouse is a powerful
model of disrupted vitamin D–VDR signalling and
inefficient utilization of vitamin D in the CNS. Of
note, several robust phenotypes of the VDR-/-
mouse have been revealed. In particular, acceler-
ated ageing was clearly observed in VDR-/- mice
[35], which may contribute to cognitive and
behavioural deficits in these mice. Consistently,
mild cognitive deficits have been shown in VDR-/-
mice [36]. Elevated anxiety and neophobia were
also seen across multiple tests in these mice on
several different background strains [37]. Altered
instinctive and social behaviours, evidenced by
aberrant maternal behaviours, were also reported
[38]. In addition, progressive decline in sensory
abilities (especially hearing and balancing) of
VDR-/- mice [39] together with several motor
abnormalities [37, 40] have been demonstrated.
These factors may also contribute nonspecifically
to overall cognitive decline and aberrant pheno-
types.
In general, findings from mouse models seem to
parallel accumulating clinical evidence in various
neurobehavioural domains. The specific issue of
changes in the brain (i.e. the organ that supports
high-level functions) related to vitamin D depriva-
tion should be considered.
Consequences of vitamin D deprivation on brain
structures
Few studies have investigated the effect of inade-
quate vitamin D status on brain structures. In
terms of brain volumetry, it was shown that rats
born to vitamin D-deficient mothers had profound
alterations in the brain at birth compared to
control animals, with a thinner cortex and
enlargement of the lateral ventricles [41]. In
humans, no significant difference in whole-brain
volume and sulcal grade according to serum
vitamin D levels was observed in one study [42],
whereas in another one, an association between
vitamin D concentration and ventricular volume (a
proxy for brain atrophy) was found in older adults
[43]. This difference only applied to the main
ventricular bodies, and not to the temporal horns.
Consistently, no difference in hippocampal volume
was reported according to vitamin D levels
amongst older community dwellers in the former
study [42].
Studies in rats to examine brain vascular changes
showed that vitamin D attenuated cortical infarc-
tion induced by cerebral arterial ligation [44]. In
humans, a meta-analysis showed clearly, in both
cross-sectional and longitudinal studies, that the
risk of stroke was increased with hypovitaminosis
D [45]. Of interest, this finding was also true for
more subtle changes such as white matter damage
[42], which is thought to disrupt cortical–subcor-
tical white matter tracts that connect important
cognitive regions of the brain [46]. Thus, it is
possible that cerebrovascular changes linked to
Fig. 1 Potential targets and
neuroprotective roles of vitamin
D during the natural history of
Alzheimer’s disease.
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hypovitaminosis D could explain some higher-level
disorders in older adults.
Vitamin D deprivation and cognitive disorders:
observational approach in older adults
Recent large and representative epidemiological
population-based studies have been conducted to
examine the relationship between hypovitaminosis
D and cognitive disorders/ADRDs [9]. Subsequent
meta-analyses confirmed that a low vitamin D
concentration in older adults is associated with
reduced cognitive performance [10, 12, 13], and is
more prevalent in those with AD [11, 12]. Never-
theless, the possibility of reverse causality remains
a major concern; in other words, does hypovita-
minosis D contribute to cognitive decline or does
cognitive decline lead to hypovitaminosis D? [27].
Importantly, further longitudinal prospective stud-
ies [47–49] have helped to establish the temporal
sequence between hypovitaminosis D and cognitive
disorders, showing that older individuals with
lower vitamin D concentrations had a significantly
increased risk of global cognitive decline and
executive dysfunction compared to those with
higher concentrations [13]. Moreover, in addition
to effects on cognitive decline, preliminary studies
confirmed that low vitamin D was associated with
an increased risk of AD [50] and incident all-cause
dementia [51]. Overall, there is evidence from
observational studies indicating that low vitamin
D concentrations contribute to the occurrence of
cognitive decline and dementia in older adults.
Vitamin D supplements and cognition: intervention-
al approach
Few intervention studies have been conducted spe-
cifically to test the effect of vitamin D supplements
on cognitive function. Of interest, observational
studies have reported that ahigher intake of vitamin
D (whether from food, supplementsor sunexposure)
is associated with better cognitive function in older
individuals [27]. For instance, consuming more
than 800 IU of vitamin D per day resulted in a
fivefold reduction in the risk of AD after 7 years of
follow-up [52]. This neuroprotective effect has been
further confirmedbybefore–after studies andquasi-
experimental studies reporting cognitive improve-
mentafter vitaminDsupplementation in the general
population of seniors [53] as well as in patients who
alreadyhavesymptomsofADRDs [54].Thecognitive
benefits of supplementation appear from 4 weeks
[55] and seem to be particularly strong for
executive function and processing speed [13].
Supraphysiological doses may not be necessary to
exert a cognitive effect [54], and consensual
supplementation, with the objective to raise the
concentration of 25OHD above 30 ng mL1 (i.e.
75 nmol L1), appears to be sufficient [56].
Consensus finding
Following this overview of the different aspects of
‘vitamin D and cognition in older adults’, the
experts expressed and discussed their position on
the following five key questions (Table 1).
Can hypovitaminosis D be considered an aetiolog-
ical/risk factor for cognitive disorders/ADRDs?. In
response to the first question (Table 1), all experts
agreed that hypovitaminosis D (and/or the ineffi-
cient utilization of vitamin D) can be considered a
aetiological/risk factor for cognitive decline and for
dementia in general. This notion is supported in
part by experimental evidence showing an action of
vitamin D in the CNS [3–8], and primarily by
prospective longitudinal studies in humans, which
have consistently demonstrated that vitamin D
concentration in older adults is associated with
subsequent cognitive change and, in particular,
that hypovitaminosis D predicts incident occur-
rence of cognitive decline and dementia [13, 48–51].
In addition, it is noteworthy that several preclinical
studies have shown that the genetic polymorphism
of VDR explains the existence of responders and
nonresponders to vitamin D and modulates the
neuroprotective efficiency of vitamin D, thus
explaining a higher rate of ADRDs in nonresponders
[30, 31]. For instance, a significant association was
shown between the VDR gene APA1 polymorphism
and the occurrence of AD, with the ‘Aa’ genotype
increasing by 2.3-fold the risk of developing AD
compared to the ‘AA’ genotype [30]. Also in the same
study, the ‘AATT’ combined genotype was found to
be less common in patients with AD than in healthy
control subjects [30].
Can serum vitamin D status be considered a useful
biomarker for the diagnosis of ADRDs?. In
response to the second question (Table 1), all
experts except one (CA) agreed that the concentra-
tion of serum25OHDcannot beusedas abiomarker
of ADRDs. The arguments in favour of its use as a
biomarker were that 25OHD is the most effective
indicator of vitamin D status and can be considered
as a ‘biological indicator characterizing pathological
processes’ according to the definition of the World
HealthOrganization [57]. For example, in a previous
meta-analysis, it was shown that the probability
C. Annweiler et al. Review: Vitamin D and cognition
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that an individual without AD would have a higher
serum 25OHD concentration than an individual
with AD was 140% if both were selected randomly
from a population [11]. The arguments against the
use of serum 25OHD as a biomarker were that
hypovitaminosis D is too common in older adults [1,
2] and that it is not sufficiently specific to be an
efficient biomarker of ADRDs, or to be useful for the
screening or diagnosis of ADRDs or for evaluating
the responseor tolerance tomedical treatment.After
discussion, the expert (CA) agreed that a systematic
serum vitamin D determination is not justified as a
biomarker for thediagnosis ofADRD,but added that
the prevalence of hypovitaminosis D is sufficiently
high in thosewith cognitive disorders/ADRDs that a
vitamin D assay is justified in this population to
detect and supplement the probable hypovitamino-
sis D. This addition was approved by all experts.
Finally, the group noted that the potential of other
vitamin D-related proteins such as the vitamin D-
binding protein (VDBP) should not be dismissed,
and evaluation in larger studies is required [58, 59].
Can serum vitamin D status be considered useful
for determining the prognosis of ADRDs?. In
response to the third question (Table 1), all
experts agreed that it is impossible at present to
determine whether vitamin D status is a prog-
nostic marker for ADRDs, as no studies have yet
examined the risk of cognitive decline according
to vitamin D status in patients with ADRDs.
Specifically, it is unclear whether patients with
hypovitaminosis D progress more quickly to a
more severe stage of dementia than patients with
higher vitamin D levels. Of note, such studies in
nondemented individuals have shown that hypo-
vitaminosis D predicted a faster and greater
cognitive decline compared to higher vitamin D
levels [47–49], suggesting that this may also be
the case in patients with ADRDs. It was stated
that studies addressing this specific issue are
required.
Can serum vitamin D status explain part of the
variability in symptoms of ADRDs in older adults?. In
response to the fourth question (Table 1), all experts
agreed that vitamin D can explain, at least in part,
the diversity of symptoms in ADRDs. First, hypovi-
taminosis D affects many organs other than the
brain and has been associated with numerous
diseases such as hypertension, type 2 diabetes,
vascular disease and osteoporosis, as well as the
propensity to fall [1, 2] (Fig. 2). All these conditions
may be found in patients with both ADRDs and
hypovitaminosis D, thus affecting patients’ func-
tional independence and the clinical presentation.
Secondly, on the basis of animal experiments using
VDR-/- mice, it appears that genetic polymor-
phisms of VDR may regulate the efficiency of vita-
min Duse, resulting not only in cognitive but also in
various noncognitive manifestations [35–40]. It was
thus concluded that alterations in the vitamin D/
VDR axis might explain part of the variability in
clinical characteristics observed in ADRDs.
Should vitamin D supplementation be part of the
care management of older adults with cognitive
disorders/ADRDs?. In response to the final ques-
tion (Table 1), all experts except one (TS) agreed
that vitamin D supplements should be part of the
care management of older adults with cognitive
disorders/ADRDs (Table 1). The arguments
against vitamin D supplementation in this popu-
lation were based on the small number of clinical
trials in the field, and the lack of well-conducted
randomized clinical trials (RCTs) to test the effec-
tiveness of vitamin D supplements against pla-
cebo in patients with ADRDs [27]. Arguments in
Fig. 2 Relationship between
vitamin D and Alzheimer’s dis-
ease/vascular dementia: an
overview of the different condi-
tions, mechanisms and inter-
actions that may be involved.
Arrows represent the causal
direction of the influences.
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favour of this option were discussed. First, the
results of the few reported clinical trials were
generally positive [53–56]. In particular, despite
their design limitations, before–after studies have
shown cognitive improvements, mainly of execu-
tive functions, after vitamin D supplementation,
as highlighted by a meta-analysis [13]. Secondly,
whilst vitamin D repletion has positive effects on
the brain as well as on a number of other organs
[1, 2], with substantial benefits in terms of
survival [60, 61], no adverse effects have been
reported for consensual supplementation [62],
which reduces the risk of this practice. After
discussion, the expert (TS) agreed that patients
with both cognitive decline/ADRDs and hypovita-
minosis D should receive vitamin D supplemen-
tation, but added that this advice is not specific
for cognitive decline/ADRDs and is justified by all
the expected bone and nonbone effects of vitamin
D supplementation. This addition was approved
by all experts.
Discussion
The summit enabled international experts to adopt
a common position on five issues of primary
importance for clinicians and researchers inter-
ested in the relationship between vitamin D and
cognition. It was concluded that hypovitaminosis
D and the inefficient utilization of vitamin D
increase the risk of cognitive decline/ADRDs in
older adults and may alter the clinical presentation
of the disease, particularly as a consequence of
accompanying morbidities; however, current evi-
dence is insufficient to recommend hypovitamino-
sis D as a reliable diagnostic or prognostic
biomarker of cognitive decline/ADRDs. Moreover,
the experts recommended correcting hypovitamin-
osis D in individuals with cognitive decline/AD-
RDs. However, this advice was not specific for
cognitive decline/ADRDs, and further well-con-
ducted RCTs are required to test more specifically
the causal relationship between hypovitaminosis D
and cognitive decline/ADRDs. Finally, the follow-
ing new approaches and research questions were
debated.
The need to consider both brain and nonbrain effects of vitamin D
when examining cognition
Ageing is accompanied by an increased incidence
of both dementia and chronic conditions, such as
cardiovascular disease, neurosensorial deficits
and osteoporosis [63]. In fact, there is a close
inter-relationship between these disorders. On one
hand, dementia may alter the prognosis and
management of other chronic diseases. On the
other hand, chronic diseases can precipitate the
evolution of dementia, changing the clinical pre-
sentation and accelerating the loss of indepen-
dence, which is the major determinant of patients’
quality of life. Of note, the action of vitamin D is
not confined to the brain; vitamin D also affects
multiple other tissues and organs, and age-related
hypovitaminosis D has been associated with a
number of conditions, including vascular disease,
hearing loss, loss of visual acuity and osteoporosis
[1, 2, 64]. This complicates the interpretation of
the impact of vitamin D on cognition. The different
possible interactions between socio-demographic
characteristics of older adults, their vitamin D
status and the brain and nonbrain determinants
of dementia are shown in Fig. 2. To better under-
stand the effect of vitamin D on these interactions,
a model was proposed (Fig. 3) in which A, the
cognitive performance, is ‘balanced’ against B, the
performance/health/function of another organ/
tissue of the body that is related to neurocogni-
tion. Scenario 0 in Fig. 3 represents the ground
state, with basal functioning of cognition (A) and
of the other condition related to neurocognition
(B). Four other scenarios are shown in which the
A/B balance changes following vitamin D supple-
mentation. The first scenario corresponds to an
overall improvement in both A and B (e.g.
improvement in hypertension and cognition fol-
lowing addition of vitamin D) [65]. The second
scenario corresponds to an overall deterioration in
A and B (e.g. vascular calcification and deteriora-
tion in cerebrovascular health following addition
of vitamin D) [66]. The third scenario corresponds
to an improvement in A, but a deterioration in B
(e.g. cognitive enhancement but transient
increased risk of falls following addition of a high
dose of vitamin D) [67]. Finally, the fourth sce-
nario corresponds to an improvement in B accom-
panied by a deterioration in A (e.g. increased
calcium absorption in the digestive tract following
addition of vitamin D with a consequent amelio-
rative effect on secondary osteoporosis, but a
deleterious effect on vascular calcification and
cerebrovascular health) [66]. Thus, due to the
ubiquitous role of vitamin D, elucidating its cog-
nitive effects is more complex than investigating
only the cerebral actions, and future basic and
clinical studies should take into account all the
effects of vitamin D in the body, particularly with
regard to morbidity burden.
C. Annweiler et al. Review: Vitamin D and cognition
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The ‘critical periods’ hypothesis
The discussion of the action of vitamin D in the
CNS also raised the possibility of ‘critical periods of
life’ during which vitamin D may have the greatest
impact on the CNS and during which sufficient
vitamin D would be essential. Previous studies
have shown that variables related to the develop-
ment of ADRDs are present at particular times of
life, commonly long before the onset of disease [68].
A proposed representation of neurocognitive func-
tion is shown graphically in Fig. 4a. We have
identified a period of rapid neurobehavioural
development during the prenatal stage (especially
gain of brain volume, and also gain of brain
function) and younger ages (especially gain of
function, and also gain of volume), a plateau phase
corresponding to adulthood and finally a phase of
brain volume and function loss corresponding to
older ages. In this model, the curve is similar to
that of the well-known lifetime changes in bone
mass [69]. For prevention of osteoporosis in
women, it is important to (i) reach a peak in bone
mass as high as possible at the end of the growth
period, and (ii) reduce the slope of decline as much
as possible after the menopause [69]. With similar
logic, based on the neurophysiological effects of
vitamin D, we suggest that there are three critical
periods in which cognitive impairment in the
elderly can be prevented: (i) during the prenatal
period when vitamin D may have a beneficial effect
on neurological development (Fig. 4b); (ii) at youn-
ger ages during which vitamin D would increase
cognitive abilities and enhance cognitive reserve
(Fig. 4c); and (iii) at older ages during which
vitamin D would prevent neurocognitive loss
(Fig. 4d).
These assumptions are consistent with previous
experiments in animals. Specifically, it has been
shown that rats born to vitamin D-deficient
mothers had profound brain alterations at birth
[41], consistent with altered signals for neuronal
differentiation [41]. The continuing brain changes
after restoration of a normal vitamin D-containing
diet [70], together with the observation of abnor-
mal adult behaviours [71], suggested that prena-
tal hypovitaminosis D disrupted not only brain
development but also adult brain functioning.
Additionally, in humans, although an association
between cognitive disorders and hypovitaminosis
D has been reported during the foetal period [72,
73] and older ages [9–13], no studies conducted
amongst younger adults have found an associa-
tion between vitamin D and cognitive perfor-
mance [74]. This suggests that vitamin D may
play a crucial role in enhancing neurocognition
during foetal development, growth and senes-
cence, but less of (or no) role during adulthood.
Such suggestions should be confirmed by further
Fig. 3 Schematic diagram of
the possible influences of vita-
min D supplements on the bal-
ance between cognition (a) and
comorbidities (b). See text for
further details and examples.
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studies, but could justify public health measures
to systematically provide supplements for preg-
nant women, young children and elderly in order
to prevent cognitive and behavioural disorders.
Vitamin D: is there an ‘active’ or ‘passive’ influence on
neurocognition?
The attempt to elucidate the mechanism of action
of vitamin D on neurocognition raised the issue of
whether lower levels/inefficient utilization of vita-
min D are causal factors that ‘actively’ trigger
ADRDs or risk factors that ‘passively’ abolish CNS
protection against ADRDs. The rationale for active
involvement of hypovitaminosis D in the genesis of
ADRDs is based on the involvement of vitamin D in
neurophysiology (i.e. its neurotrophic role and the
regulation of neurotransmitters) [4–8], with the
possibility that vitamin D insufficiency results in a
pathological dysfunction of the brain leading to
ADRDs. An epidemiological argument against such
active involvement is based on the finding that 70–
90% of older adults have hypovitaminosis D but
most do not suffer from ADRDs [2]. Thus, the
possibility should be considered that vitamin D is
instead a neuroprotective agent, as suggested by
its antioxidant and anti-inflammatory effects [4–8],
and its insufficiency could ‘passively’ lead to
increased CNS sensitivity with a reduced response
to ‘dementiogenic’ stress. Although this question of
whether the influence on neurocognition is ‘active’
or ‘passive’ may appear trivial, the difference is in
fact crucial because it affects our future approach
to vitamin D repletion. Indeed, just enough sup-
plementation to correct hypovitaminosis D should
be sufficient if vitamin D is considered to be a
neuroprotectant, whereas much higher doses may
be considered, with the aim of boosting mental
faculties, if vitamin D ‘actively’ controls the CNS.
Furthermore, determining whether hypovitamino-
sis D is actively or passively involved in the history
of ADRDs will help to define the objectives and
outcomes of future RCTs. In other words, should
vitamin D supplementation be tested for prevent-
ing the occurrence of ADRDs, or for reducing its
symptoms? And could hypovitaminosis D be
involved in the resistance to standard antidementia
treatments? If hypovitaminosis D explains in part
(a) (b)
(c) (d)
Fig. 4 Schematic diagram of the evolution of neurocognitive health throughout life (a), and the possible influence of vitamin
D at potential critical periods: prenatal (b), younger age (c) and older age (d).
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the pathological process of ADRDs, it may also
enhance the effectiveness of standard antidemen-
tia treatments or account at least partially for the
resistance to these treatments. Although specula-
tive, this suggests that clinicians should restore
vitamin D levels before starting antidementia treat-
ments or use vitamin D as an adjunct to standard
treatments. In line with this, a recent 6-month
controlled trial demonstrated that the combination
of memantine+vitamin D was superior to either
memantine or vitamin D alone in preventing cog-
nitive decline amongst participants with AD [75]. In
fact, those taking both treatments had a clinically
relevant and statistically significant gain of 4
points on the Mini-Mental State Examination score
of cognitive function. These results were consistent
with the finding of an in vitro study of less
degeneration of cortical axons after exposure to
Ab peptide or glutamate in microfluidic neuronal
cultures enriched with memantine plus vitamin D
compared to control medium and cultures
enriched with either memantine or vitamin D alone
[76].
Conclusions
In conclusion, this first task force on ‘Vitamin D
and Cognition in Older Adults’ enabled interna-
tional experts to reach agreement that hypovita-
minosis D and the inefficient utilization of vitamin
D increase the risk of cognitive decline/ADRDs in
older adults and may alter the clinical presentation
of the disease, particularly as a consequence of
accompanying morbidities; however, at present,
hypovitaminosis D should not be used as a diag-
nostic or a prognostic biomarker of cognitive
decline/ADRDs due to lack of specificity and
insufficient evidence. The experts also recom-
mended measurement of serum 25OHD because
of the high prevalence of hypovitaminosis D in this
population and supplementation, if necessary.
However, this advice was not specific for ADRDs
in the absence of well-conducted RCTs.
Future studies should consider the effects of vita-
min D on comorbidities and explore the stimulat-
ing and/or protective effects of vitamin D on
neurocognition at different stages of life. A stronger
focus on the role of vitamin D-related genetic
variance (e.g. in the genes encoding VDR,
a-hydroxylase or VDBP) in humans will also be
important. In parallel, conditional and brain-spe-
cific VDR mutations are eagerly expected to assess
their neurophenotypes. Critical evaluation (and
bridging, if possible) of the clinical and animal
models using altered vitamin D systems available
in the field (e.g. VDR-/-, developmental vitamin D
deficit, acute and chronic vitamin D treatment or
depletion) should also be carried out in order to
best interpret neurocognitive and behavioural
abnormalities associated with vitamin D depriva-
tion. Focusing on the threshold concentration of
25OHD required to prevent these adverse events,
and on the dose of supplementation required, will
also be important.
Finally, it will be necessary to revise the current
document in due course, probably within the next
3–5 years, when significant evidence is available
regarding the different aspects of the recommen-
dations. It is hoped that there will be an expansion
of high-quality research activities that either cor-
roborate or lead to modification of these recom-
mendations.
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